GenMark Diagnostics, Inc. (NASDAQ:GNMK) SVP Jennifer Anne Williams sold 2,719 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $4.74, for a total transaction of $12,888.06. Following the completion of the transaction, the senior vice president now directly owns 152,709 shares in the company, valued at $723,840.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jennifer Anne Williams also recently made the following trade(s):

  • On Friday, September 15th, Jennifer Anne Williams sold 38,681 shares of GenMark Diagnostics stock. The stock was sold at an average price of $9.08, for a total transaction of $351,223.48.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) traded up $0.07 during trading on Tuesday, reaching $4.71. 425,851 shares of the company traded hands, compared to its average volume of 423,827. GenMark Diagnostics, Inc. has a 52-week low of $3.63 and a 52-week high of $13.67. The company has a quick ratio of 2.77, a current ratio of 2.97 and a debt-to-equity ratio of 0.12.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.02). GenMark Diagnostics had a negative return on equity of 100.33% and a negative net margin of 116.76%. The firm had revenue of $11.60 million for the quarter, compared to analyst estimates of $14.56 million. During the same quarter in the previous year, the business posted ($0.27) earnings per share. GenMark Diagnostics’s revenue for the quarter was up 7.4% on a year-over-year basis. equities research analysts predict that GenMark Diagnostics, Inc. will post -1.17 earnings per share for the current year.

WARNING: “GenMark Diagnostics, Inc. (GNMK) SVP Sells $12,888.06 in Stock” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/21/genmark-diagnostics-inc-gnmk-svp-sells-12888-06-in-stock.html.

A number of institutional investors have recently added to or reduced their stakes in GNMK. BlueCrest Capital Management Ltd acquired a new stake in GenMark Diagnostics during the second quarter worth about $126,000. Legal & General Group Plc increased its position in GenMark Diagnostics by 2.1% during the second quarter. Legal & General Group Plc now owns 11,521 shares of the medical equipment provider’s stock worth $137,000 after purchasing an additional 240 shares during the last quarter. Susquehanna International Group LLP acquired a new stake in GenMark Diagnostics during the second quarter worth about $137,000. Quantitative Systematic Strategies LLC increased its position in GenMark Diagnostics by 18.4% during the second quarter. Quantitative Systematic Strategies LLC now owns 13,147 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 2,047 shares during the last quarter. Finally, Wrapmanager Inc. acquired a new stake in shares of GenMark Diagnostics during the third quarter valued at about $172,000.

Several research firms have recently weighed in on GNMK. Bank of America Corporation began coverage on shares of GenMark Diagnostics in a research note on Monday, September 18th. They issued a “buy” rating and a $13.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of GenMark Diagnostics in a research note on Wednesday, October 4th. BTIG Research reissued a “buy” rating and issued a $13.00 price target on shares of GenMark Diagnostics in a research note on Thursday, August 31st. Canaccord Genuity reissued a “buy” rating and issued a $14.00 price target on shares of GenMark Diagnostics in a research note on Monday, October 30th. Finally, Raymond James Financial, Inc. reissued a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. GenMark Diagnostics currently has a consensus rating of “Hold” and a consensus target price of $11.80.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.